latest update:
[TrialBase DB]

trial summary · NCT07125183

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

A Phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma of Soft Tissue

Trial record from the TrialBase DB dataset, status RECRUITING, condition Sarcoma, sponsored by University of Colorado, Denver. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07125183phase PHASE2enrollment 20start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The overall goal of this Phase 2 study is to determine the efficacy of a lower dose weekly schedule of doxorubicin in patients with unresectable leiomyosarcomas aged 65-100 years old. While doxorubicin is the standard of care therapy for sarcomas not removable by surgery, older or more frail patients may struggle to tolerate side effects of the treatment including immune cell suppression. Previous studies have suggested that similar anti-tumor activity can be obtained using a lower dose, weekly administration schedule of doxorubicin. In this study, the investigators will determine progression-free survival rate at 12 weeks, with secondary endpoints including quality of life and adverse events in this population. Importantly, doxorubicin can also induce immune stimulatory effects when administered at lower doses, based on animal data. Thus, correlative samples including blood and tumor biopsies will also explore the effects of immune cells and foreignness of the tumor prior to and during treatment in study patients.

Source record: https://clinicaltrials.gov/study/NCT07125183

Facts

registry idNCT07125183
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionSarcoma
sponsorUniversity of Colorado, Denver
sponsor classOTHER
enrollment20
start date2026-12
primary completion2028-12
completion2029-12
results postednot reported

Conditions

  • Sarcoma

Interventions

  • Doxorubicin

Countries

  • United States

Intervention types: DRUG

Work with this record